New Delhi, Jan 4 (PTI) Drug firm Lupin on Thursday said it has received approval from the US health regulator to market a generic medication to treat diabetes.

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Dapagliflozin and Saxagliptin tablets, the Mumbai-based drug maker said in a regulatory filing.

Also Read | RPF Recruitment 2024: Notification Released For 2,250 Constable and SI Posts; Know Age Limit, Educational Qualification and Other Details.

The company's product is a generic equivalent of AstraZeneca AB's Qtern tablets, it added.

This generic product will be manufactured at its Pithampur facility, the company said.

Also Read | GATE 2024 Admit Card for Graduate Aptitude Test in Engineering Examination Likely To Be Released Today at gate2024.iisc.ac.in, Know How To Download.

Dapagliflozin and Saxagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

As per IQVIA data, Dapagliflozin and Saxagliptin tablets had estimated annual sales of USD 5 million in the US market.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)